Welcome to NeurologyLive®‘s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®‘s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Future Research on the Pathogenesis of COVID-19, Cognitive Changes: Joanna Hellmuth, MD, MS
The cognitive neurologist at the University of California San Francisco discussed the need to continue research on why patients develop cognitive changes following COVID-19 infection and how clinicians can care for them, stressing the importance of developing more objective data to legitimize patients’ conditions.
2: Mind Moments Episode 57: Invisible Symptoms: Cognition and MS
Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Dhanashri P. Miskin, MD, who offered her insight into the role that cognitive impairment plays as a symptom of multiple sclerosis, the current approach to treatment and management for patients, and what challenges remain for the field to address.
3: NeuroVoices: Imad Najm, MD, on Aiming to Prevent Neurological Disorders Before Symptom Onset
The director of Cleveland Clinic’s Epilepsy Center discussed the new Cleveland Clinic Brain Study, which will evaluate predisease fingerprints from patients who go on to develop neurological disorders, with an aim of uncovering more about the mechanisms of brain diseases and ultimately lead to the design of preventive treatment for them.
4: Insights: The Importance of Different Tests When Caring For Patients With AD
In Episode 7 of the NeurologyLive® Insights™ series, “Testing for Early Diagnosis of Alzheimer’s Disease,” Alireza Atri, MD, PhD, concludes with a discussion on how different testing methods impact the care of patients with Alzheimer diease.
5: Racial Subgroup Data Heavily Underreported in MS Trials, Lack of Non-White Representation
Almost 40% of the studies assess did not report racial or ethnic subgroup data. Geographically, there was a slight increase in the number of South American-based phase 3 DMT trials and almost little-to-no improvement in the phase 3 DMT studies based in Africa.